PROTAC technology (proteolysis targeting chimeric molecules)

	Next higher product group	protein degradation technology
	Person	Crews, Craig (Yale Univ 201205 Professor Molecular, Cellular + Developmental Biology + Prof Chemistry + Pharmacology)

Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for PROTAC technology (proteolysis targeting chimeric molecules)

[1] Boehringer Ingelheim. (12/7/20). "Press Release: Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders – a Novel Approach to Fight Cancer". Ingelheim & Vienna....
[2] Bayer AG. (10/1/19). "Press Release: Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio". Monheim, Boston, MA & New Haven, CT....
[3] Arvinas, Inc.. (6/4/19). "Press Release: Bayer and Arvinas to Collaborate on Human PROTAC Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC Applications". New Haven, CT....
[4] Arvinas, LLC. (4/4/18). "Press Release: Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform". New Haven, CT....
[5] Arvinas, LLC. (11/15/17). "Press Release: Arvinas Expands Strategic License Agreement with Genentech". New Haven, CT....
[6] Arvinas, LLC. (9/20/17). "Press Release: Arvinas Appoints Dr. John Houston as President and Chief Executive Officer". New Haven, CT....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]